Cutaneous T-Cell Lymphoma (CTCL) Completed Phase 3 Trials for Brentuximab vedotin (DB08870)

Also known as: Lymphoma, Cutaneous T-Cell / Cutaneous T-Cell Lymphomas / Cutaneous T-Cell Lymphoma / Cutaneous lymphoma / Lymphoma, T-Cell, Cutaneous

IndicationStatusPhase
DBCOND0071861 (Cutaneous T-Cell Lymphoma (CTCL))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01578499A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)Treatment